Neurol. pro Praxi, 2004; 1: 7-10

Idiopatická µahká kognitívna dysfunkcia

doc. MUDr. Egon Kurča Ph.D
Neurologická klinika JLF UK a MFN, Martin

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kurča E. Idiopatická µahká kognitívna dysfunkcia. Neurol. praxi. 2004;7(1):7-10.

Autor podáva základné informácie o koncepcii tzv. µahkej kognitívnej dysfunkcie (mild cognitive impairment). Idiopatická µahká kognitívna dysfunkcia môľe by» klinickým predstupňom demencie najčastejąie podmienenej rozvíjajúcou sa Alzheimerovou chorobou. Z tohto dôvodu je depistáľ osôb s µahkou kognitívnou dysfunkciou a ich klinické sledovanie základným predpokladom pre moľnos» včasnej liečby demencie podmienenej hlavne Alzheimerovou chorobou. Prehµadný článok osobitne pojednáva o etiológii, klinickom obraze, epidemiológii, diagnostike, prognostike a liečbe idiopatickej µahkej kognitívnej dysfunkcie.

Kµúčové slová

µahká kognitívna dysfunkcia, pamä», demencia, Alzheimerova choroba.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Almkvist O, Axelman K, Basun H, Jensen M, Viitanen M, Wahlund LO, Lannfelt L. Clinical findings in nondemented mutation carriers predisposed to Alzheimer's disease: a model of mild cognitive impairment. Acta Neurol Scand Suppl. 2003; 179: 77-82. Go to original source... Go to PubMed...
    2. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand Suppl. 2003; 179: 47-51. Go to original source... Go to PubMed...
    3. Anstey KJ, Maller JJ. The role of volumetric MRI in understanding mild cognitive impairment and similar classifications. Aging Ment Health. 2003; 7 (4): 238-250. Go to original source... Go to PubMed...
    4. Artero S, Ritchie K. The detection of mild cognitive impairment in the general practice setting. Aging Ment Health. 2003; 7 (4): 251-258. Go to original source... Go to PubMed...
    5. Busse A, Bischkopf J, Riedel-Heller SG, Angermeyer MC; Leipzig Longitudinal Study of the Aged LEILA75+. Mild cognitive impairment: prevalence and predictive validity according to current approaches. Acta Neurol Scand. 2003; 108 (2): 71-81. Go to original source... Go to PubMed...
    6. Canadian Study of Health and Aging Working Group: study methods and prevalence of dementia. Can Med Assoc J, 1994; 150: 899-913.
    7. Chertkow H. Mild cognitive impairment. Curr Opin Neurol, 2002; 4: 401-407. Go to original source... Go to PubMed...
    8. Clarke R, Harrison G, Richards S. Vital Trial Collaborative Group. Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. J Intern Med. 2003; 254 (1): 67-75. Go to original source... Go to PubMed...
    9. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003; 25 (1): 178-193. Go to original source... Go to PubMed...
    10. Drachman D. If we live long enough, will we all be demented? Neurology, 1994; 44: 1563-1565. Go to original source... Go to PubMed...
    11. Ebly EM, Hogan DB, Parhad IM. Cognitive impairment in the nondemented elderly: results from the Canadian Study of Health and Aging. Arch Neurol, 1995; 52:612-619.
    12. Grundman M, Petersen RC, Morris JC, et al. ADSC Cooperative Study. Rate of dementia of the Alzheimer type (DAT) in subjects with mild cognitive impairment. Neurology, 1996; 46: A403.
    13. Hampel H, Goernitz A, Buerger K. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. Brain Res Bull. 2003; 61 (3): 243-253. Go to original source... Go to PubMed...
    14. Han X, Fagan AM, Cheng H, Morris JC, Xiong C, Holtzman DM. Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol. 2003; 54 (1): 115-119. Go to original source... Go to PubMed...
    15. Huang C, Wahlund LO, Almkvist O, Elehu D, Svensson L, Jonsson T, Winblad B, Julin P. Voxel - and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment. Neuroimage. 2003; 19 (3): 1137-1144. Go to original source... Go to PubMed...
    16. Ihl R. The impact of drugs against dementia on cognition in aging and mild cognitive impairment. Pharmacopsychiatry. 2003; 36 (Suppl 1): S38-43. Go to original source... Go to PubMed...
    17. Jelic V, Winblad B. Treatment of mild cognitive impairment: rationale, present and future strategies. Acta Neurol Scand Suppl. 2003; 179: 83-93. Go to original source... Go to PubMed...
    18. Knopman DS, Boeve BF, Petersen RC. Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia. Mayo Clin Proc. 2003; 78 (10): 1290-1308. Go to original source... Go to PubMed...
    19. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol. 2003; 18 (2): 61-71. Go to original source... Go to PubMed...
    20. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early stage Alzheimer disease. Arch Neurol, 2001; 58: 397-405. Go to original source... Go to PubMed...
    21. Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol. 2003; 54(3):343-51. Go to original source... Go to PubMed...
    22. Saez-Valero J, Fodero LR, Sjogren M, Andreasen N, Amici S, Gallai V, Vanderstichele H, Vanmechelen E, Parnetti L, Blennow K, Small DH. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. J Neurosci Res. 2003; 72(4):520-6. Go to original source... Go to PubMed...
    23. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289(20):2651-62. Go to original source... Go to PubMed...
    24. Stam CJ, van der Made Y, Pijnenburg YA, Scheltens P. EEG synchronization in mild cognitive impairment and Alzheimer's disease. Acta Neurol Scand. 2003; 108(2):90-6. Go to original source... Go to PubMed...
    25. Tan RS, Pu SJ, Culberson JW. Role of androgens in mild cognitive impairment and possible interventions during andropause. Med Hypotheses. 2003; 60(3):448-52. Go to original source... Go to PubMed...
    26. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003; 74(9):1200-5. Go to original source... Go to PubMed...
    27. Wahlund LO, Pihlstrand E, Jonhagen ME. Mild cognitive impairment: experience from a memory clinic. Acta Neurol Scand Suppl. 2003; 179:21-4. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.